From 2003 to 2013, Trinity Pharma has grown from a regulatory business to a respected full service pharmaceutical company with a unique value proposition. The company now provides product commercialisation capabilities in Southern Africa for an extensive range of healthcare products, in addition to their regulatory consultancy services in the Southern African market.


Trinity Pharma was founded to fulfil the applicant role for international pharmaceutical companies wishing to enter the South African market. The founding team included 3 highly experienced regulatory consultants with strong ties to the various South African pharmaceutical regulatory agencies.


TriVest, seizing the opportunity to offer a wider set of advisory services to Trinity Pharma's clients, acquired 80 % of the shares. One of the firm's major differentiators at the time was Trinity Pharma's strong reputation for high quality work and their ability to advise on the registration of a wide spectrum of pharmaceutical products. 


TriVest acquired 100% of the shares. With the additional support provided by TriVest's networks and operational expertise, Trinity Pharma commenced its evolution into a pharmaceutical business with full commercialisation capabilities.


In April, Gaby Simaan joined Trinity Pharma as a shareholder and Managing Director. His pharmaceutical industry experience and networks completed the transition of Trinity Pharma into having a commercialisation division.


Trinity Pharma acquired a basket of registered products from local pharmaceutical companies. Off-take agreements were signed with a retail pharmacy chain for a 5 year period.


An international pharmaceutical company based in Australia, UK and India acquired a shareholding in Trinity Pharma, in order to benefit from Trinity Pharma’s aggressive growth strategy. The deal was of mututal benefit as Trinity was then exposed to their new partner’s product pipeline and international customer base.